Update shared on 17 Dec 2025
Fair value Increased 0.065%Analysts have nudged their price target on AXA slightly higher to approximately €45.07 from about €45.04, citing a marginally lower discount rate and modest improvements in projected profit margins that together support a slightly richer valuation multiple.
Valuation Changes
- Fair Value has risen slightly from approximately €45.04 to about €45.07, reflecting a marginal uplift in the intrinsic valuation estimate.
- Discount Rate has fallen slightly from roughly 6.85 percent to around 6.79 percent, supporting a modestly higher valuation multiple.
- Revenue Growth expectations are essentially unchanged at about 9.83 percent, indicating a stable top line outlook.
- Net Profit Margin has risen slightly from roughly 7.19 percent to about 7.21 percent, pointing to a minor improvement in projected profitability.
- Future P/E has fallen slightly from around 12.44x to about 12.40x, suggesting a marginally lower forward earnings multiple despite the higher fair value estimate.
Have other thoughts on AXA?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.